Hong Kong flu

Around May 2020, researchers published a fifty‑year retrospective on the evolution and impact of influenza A(H3N2) following the 1968 pandemic. The study examined viral persistence, antigenic changes, and the public health legacy of the Hong Kong flu, highlighting the long‑term significance of the pandemic in global disease surveillance.

By September 1970, the H3N2 virus strain responsible for the Hong Kong flu had displaced the previously circulating H2N2 strain and established itself as a dominant seasonal influenza subtype globally. This marked the virus’s permanent integration into annual cycles of flu activity.

By March 1970, the Hong Kong flu pandemic had largely receded worldwide. Following the intense second wave of 1969–1970, influenza activity declined significantly in most regions. The H3N2 strain, however, transitioned into seasonal influenza, continuing to circulate in subsequent decades.

By December 27, 1969, the second wave of the pandemic peaked in the United Kingdom, where hospitals—including those in London and Birmingham—experienced severe strain. Wards declared red alerts, restricting admissions to urgent cases only, signaling the high burden on healthcare systems during a second, more impactful wave.

On October 22, 1969, the CDC and Emory University, in conjunction with WHO, convened an international conference in Atlanta to review the origin, global spread, and control measures of the Hong Kong flu. Discussions covered vaccine strategies and insights from affected countries, shaping future pandemic preparedness practices.

Entering early 1969, the initial pandemic wave began to subside in parts of Europe and Asia. In countries such as Japan and the UK, localized outbreaks diminished by February–March, although a more severe second wave would emerge later. This transitional period offered respite and guidance for public health authorities dealing with future waves.

On December 21, 1968, the Apollo 8 astronauts received vaccinations against the Hong Kong influenza ahead of their moon‑orbiting mission. This measure reflected the perceived high transmissibility of the virus and represented an early intersection of space exploration and pandemic preparedness.

By December 1968, the H3N2 virus had become widespread in the United States, facilitated in part by soldiers returning from the Vietnam War. The rapid spread prompted widespread epidemiological monitoring and led to increased public health interventions during the winter season.

In November 1968, within approximately a month of WHO’s alert, vaccine production commenced in the United States. Merck, Sharp & Dohme pledged eight million doses of A2 Hong Kong strain vaccine, with the first million doses becoming available that month. This rapid development marked a significant milestone in pandemic mitigation via immunization.

On August 16, 1968, following confirmation that the virus strain was antigenically distinct from previous influenza viruses, the World Health Organization issued a global warning about the Hong Kong influenza variant. This alert prompted international awareness and preparedness efforts, highlighting the severity and novelty of the emerging pandemic threat.

On July 17, 1968, the University of Hong Kong’s National Influenza Center isolated the new influenza A(H3N2) virus and sent specimens immediately to the World Influenza Center in London and to the CDC’s International Influenza Center in Atlanta. This rapid sharing of virus samples enabled early international recognition and research into the novel strain, facilitating vaccine development and global pandemic response coordination.

On July 13, 1968, Hong Kong clinics experienced a sudden and large increase in patients presenting with influenza‑like illness, recording about 500,000 cases—the most significant outbreak since the 1957 Asian flu pandemic. This unusual surge marked the emergence of what would become known as the Hong Kong flu. Rapid identification and first isolation of the novel H3N2 strain followed shortly thereafter. The event signaled the beginning of the pandemic with significant implications for global surveillance and response.